nicotine addiction

AZD-8529 mesylate is a highly selective, and orally bioavailable positive allosteric modulator of mGluR2 (EC50: 285 nM). It shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

(S)-UFR2709 is a competitive antagonist of the nicotinic acetylcholine receptor (nAChR), showing greater affinity for α4β2 nAChRs over α7 nAChRs. It effectively reduces anxiety, ethanol consumption, and ethanol preference in alcohol-preferring rats, functions as an anxiolytic agent, and holds potential for investigating nicotine addiction.

Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction. Pozanicline selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a no

(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist with higher affinity for α4β2 nAChRs than for α7 nAChRs. It decreases anxiety and reduces ethanol consumption and preference in alcohol-preferring rats. As an anxiolytic agent, (S)-UFR2709 (hydrochloride) can be used for the study of nicotine addiction[1][2].

Varenicline dihydrochloride is a Selective α4β2 nicotinic acetylcholine receptor partial agonist.

CB1R Allosteric modulator 3 is a potent CB1R modulator that inhibits cAMP and β-Arrestin and can be used for the study of obesity and nicotine addiction.